曲贝替定联合聚乙二醇化脂质体阿霉素治疗复发性卵巢癌患者的真实世界疗效：单中心经验
Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
作者信息
Moriceau Guillaume, Rivoirard Romain, Méry Benoîte, Vallard Alexis, Pacaut Cécile, Trone Jane-Chloé, Espenel Sophie, Bosacki Claire, Jacquin Jean-Philippe, Magné Nicolas
出版信息
Chemotherapy. 2016;61(3):122-6. doi: 10.1159/000441378. Epub 2016 Jan 12.
BACKGROUND
Trabectedin plus pegylated liposomal doxorubicin (PLD) proved efficacious as second-line treatment for patients with recurrent ovarian cancer (ROC).
METHODS
We report a single-center retrospective analysis of the efficacy and tolerance of trabectedin 1.1 mg/m2 every 3 weeks in a cohort of real-life ROC patients.
RESULTS
From February 2012 to January 2014, 17 patients were treated with trabectedin alone or combined with PLD. Median age was 61 years (range: 48-78). Performance status was 0-1 in 16 patients (94%). Disease response rate was 53% and disease control rate was 76%. At the end of the follow-up, 8 patients (47%) were alive. Median overall survival was 17.6 months (95% CI 13.6 to not reached). Median progression-free survival was 6.7 months (95% CI 5.4-10.0). The most frequent grade 3-4 toxicities were neutropenia (n = 4, 24%) and nausea/vomiting (n = 4, 24%).
CONCLUSION
Trabectedin combined with PLD seems efficient in and well tolerated by real-life ROC patients.
背景
曲贝替定联合聚乙二醇化脂质体阿霉素（PLD）被证明对复发性卵巢癌（ROC）患者是有效的二线治疗方案。
方法
我们报告了一项单中心回顾性分析，研究了在一组真实世界的ROC患者中，每3周使用1.1mg/m²曲贝替定的疗效和耐受性。
结果
从2012年2月至2014年1月，17例患者接受了单独使用曲贝替定或联合PLD的治疗。中位年龄为61岁（范围：48 - 78岁）。16例患者（94%）的体能状态为0 - 1。疾病缓解率为53%，疾病控制率为76%。随访结束时，8例患者（47%）存活。中位总生存期为17.6个月（95%置信区间13.6至未达到）。中位无进展生存期为6.7个月（95%置信区间5.4 - 10.0）。最常见的3 - 4级毒性反应是中性粒细胞减少（n = 4，24%）和恶心/呕吐（n = 4，24%）。
结论
曲贝替定联合PLD在真实世界的ROC患者中似乎有效且耐受性良好。
Zotero 插件